PATENT CLAIM ANALYSIS

Application Number: 16164653
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "344000"]

Abstract:
The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

Claim (Index 72):
The process of  claim 71 , wherein the silver salt is selected from Ag 2 CO 3 , AgClO 4  and AgBF 4 .

Metadata:
- Claim Count in Document: 50.0
- Percentile: 97.0
- Lexical Diversity: 1.33333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14905776', '15805390', '15439308', '15439494', '15553570']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8413199715638013
- 35 USC 102 Novelty (BERT): 0.5950568442382269
- Combined Prediction Score: 0.8166936588312439
- Mean Citation Score: 584.457268
- Max Citation Score: 679.58905
- Similarity Product: 399.1201799083889

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test